Lusaris Therapeutics is a developer of novel drugs for the treatment of neurological diseases. The lead project LSR-1019 is a proprietary sublingual formulation of 5-MeO-DMT, a fast-acting and fast-clearing serotonergic hallucinogen that is being developed for use in for the treatment of drug-resistant depression and other neuropsychiatric disorders. In addition to LSR-1019, Lusaris’ pipeline includes novel neuroplasticizers for the treatment of a broad range of neuropsychiatric and neurological disorders, including migraine and cluster headache. Lusaris Therapeutics announced the completion of a $60 million Series A financing led by RA Capital Management, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Boxer Capital and another undisclosed investor.
This article is reproduced from: https://www.itjuzi.com/investevent/13644897
This site is for inclusion only, and the copyright belongs to the original author.